With an estimated 1.9 million cancer diagnoses and more than 600,000 cancer deaths forecasted in the US alone in 2021, it is more important than ever to continue the ongoing push for new, effective cancer treatments. Fortunately, there are more oncology trials in clinical development than ever before. In fact, the number of oncology trials has nearly doubled in the past 10 years. But the complexity of oncology trials has grown as well, making them more challenging to recruit and execute and more difficult to retain patients.
With competition and complexity at an all time high, you need a CRO that understands the unique challenges of oncology trials and the expertise to operationalize your study design successfully. Whether you’re embarking on your Phase I dose-finding study or gearing up for your Pivotal Phase III trial, Aperio will provide the expertise and attention your trial deserves.